Plus Therapeutics (NASDAQ:CNSY) Posts Earnings Results, Misses Estimates By $0.16 EPS

Plus Therapeutics (NASDAQ:CNSY) announced its earnings results on Friday. The company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.16), FiscalAI reports. The firm had revenue of $0.72 million for the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%.

Plus Therapeutics Stock Up 23.3%

NASDAQ:CNSY traded up $0.18 during mid-day trading on Friday, reaching $0.95. 8,046,110 shares of the company’s stock were exchanged, compared to its average volume of 1,810,277. Plus Therapeutics has a one year low of $0.43 and a one year high of $18.89. The business’s fifty day moving average is $1.70. The stock has a market capitalization of $7.21 million, a price-to-earnings ratio of -0.28 and a beta of 1.49.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on CNSY. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research note on Monday, November 2nd. Zacks Research raised Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Thursday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce”.

About Plus Therapeutics

Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.